St. Petersburg start-up makes inroads into Bavarian market

Print 23 August 2017
Marchmont Innovation News

Data MATRIX, a St. Petersburg start-up developing clinical data processing solutions, has opened a rep office in Munich, in southern Germany, and joined the Bavarian biotech cluster, Russian portal Firrma.ru  reported , citing a source in the start-up. 

Data MATRIX is reportedly expecting the new office to facilitate the Russian company’s interaction with international customers. The start-up also hopes to find prospective partners among Bavarian cluster resident companies. 

The St. Pete start-up will offer its new clients the company’s existing products and services, as well as its new R&D product for clinical trial control called CTMS. 

Set up three years ago, Data MATRIX has come up with special software to arrange and manage clinical trials. Its current portfolio reportedly includes more than 100 projects for pharmas, biotech companies, and contract research organizations (CROs). 

At the end of last year Data MATRIX raised a reported $2.8m from the Russian government-owned Internet Initiatives Development Fund (known in Russia under the FRII abbreviation) and Primer Capital, a Russian private venture fund. The start-up has used the money to step up project development and prepare for foreign market entry.

Source

Return

All Partners

All Portfolio

MEDIA CENTER

  • NovaMedica began construction of a pharmaceutical plant in the Kaluga region

    NovaMedica began construction of a pharmaceutical plant in the Kaluga region

    Russian pharmaceutical company NovaMedica, a portfolio company of RUSNANO, announces the start of construction of a plant for the production of sterile injectable drugs as part of its long-term strategy to localize innovative medicines and technologies of their development and production in Russia. The plant will be built in the industrial park “Vorsino” in the Kaluga region.

All news